Shilpa Medicare Q3 FY26 Revenue Up 28% to ₹411 Cr, EBITDA Grows 40%
Shilpa Medicare reported 3QFY26 consolidated revenue of ₹411 crore, up 28% YoY, and EBITDA of ₹115 crore, up 40% YoY. For 9MFY26, revenue was ₹1,110 crore (up 14% YoY) and EBITDA was ₹323 crore (up 26% YoY). The company launched a first-in-class NAFLD therapy in India and saw significant growth in its Formulations business.
The substantial revenue and profit growth, along with the successful launch of a novel therapy and positive future outlook, are significant developments that will likely have a high impact on the company's performance and investor perception.
The company reported strong year-on-year growth in revenue and EBITDA for both the quarter and the nine-month period. The launch of a new therapy and positive commentary from management further support a positive sentiment.
Shilpa Medicare Limited announced its financial results for the quarter and nine months ended December 31, 2025. For the third quarter of fiscal year 2026 (3QFY26), the company reported a consolidated revenue of ₹411 crore, marking a significant 28% year-on-year increase. EBITDA for the quarter surged by 40% to ₹115 crore, with EBITDA margins improving to 28% from 26% in the same period last year. Adjusted Profit After Tax (PAT) saw a substantial rise of 72% to ₹55 crore.
For the nine months ended December 31, 2025 (9MFY26), consolidated revenue reached ₹1,110 crore, a 14% increase year-on-year. EBITDA grew by 26% to ₹323 crore, and EBITDA margins improved to 29%. Adjusted PAT showed a remarkable 128% growth to ₹146 crore.
The company highlighted the launch of a first-in-class therapy for Non-alcoholic Fatty Liver Disease (NAFLD) in India under its own brand, NoducaTM. This launch, coupled with strategic partnerships with three large pharma companies, is expected to drive domestic formulation segment revenue. The Formulations vertical grew by 50% year-on-year in 3QFY26, with the EU business reporting over 100% revenue growth.
Management commentary indicated strong progress across all verticals, with 3QFY26 revenue growth of 28% year-on-year and EBITDA margins of 28%. Key achievements include EU approval for Rotigotine and successful Phase 3 trials for Ondansetron ER in India. The company is confident in a significantly better FY27, supported by its R&D foundation, product approvals, and strategic partnerships.
What to do with a filing like this
Shilpa Medicare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shilpa Medicare Limited. Read the original for the full detail.